Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
DIABETOLOGY / CLINICAL RESEARCH
The protective effect of sodium-glucose cotransporter 2 inhibitors and the incidence of ovarian cancer: a nationwide cohort preliminary study
1
Division of Cardiology, Department of Internal Medicine, Changhua Christian Hospital, Yunlin Branch, Taiwan
2
Department of Medicine and Nursing, Hungkuang University, Taiwan
3
Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taiwan
4
Institute of Medicine, Chung Shan Medical University, Taiwan
5
Department of Medical Research, Chung Shan Medical University Hospital, Taiwan
6
Department of Ophthalmology, Nobel Eye Institute, Taiwan
Submission date: 2024-08-07
Final revision date: 2024-10-16
Acceptance date: 2024-11-24
Online publication date: 2025-02-22
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are commonly used antihyperglycemic medications that also exhibit anti-inflammatory and antioxidant effects. Ovarian cancer, a common gynecological neoplasm, is associated with increased inflammation and oxidative stress. Thus, this study investigated the correlation between the usage of SGLT2 inhibitors and the incidence of ovarian cancer in a population with type 2 diabetes mellitus (T2DM).
Material and methods:
A retrospective cohort study was conducted, and patients with T2DM were divided into those who used SGLT2 inhibitors and those who did not. A total of 163 668 and 327 336 patients with T2DM were categorized into the SGLT2 inhibitor and control groups, respectively. The primary outcome was the development of ovarian cancer, as identified using diagnostic codes and laboratory examination findings. Cox proportional hazard regression was adopted to yield the adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for ovarian cancer events between the two groups.
Results:
A total of 167 and 222 patients developed ovarian cancer in the SGLT2 inhibitor and control groups, respectively. The incidence of ovarian cancer was significantly lower in the SGLT2 inhibitor group than in the control group (adjusted hazard ratio: 0.73, 95% CI: 0.60–0.89, p = 0.0023). Subgroup analysis stratified by oral medications revealed that the effect of SGLT2 inhibitors on ovarian cancer development was significantly different from the effects of biguanides, sulfonylureas, -glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors (p < 0.05).
Conclusions:
This preliminary study showed that the administration of SGLT2 inhibitors in patients with T2DM is associated with a lower incidence of ovarian cancer.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are commonly used antihyperglycemic medications that also exhibit anti-inflammatory and antioxidant effects. Ovarian cancer, a common gynecological neoplasm, is associated with increased inflammation and oxidative stress. Thus, this study investigated the correlation between the usage of SGLT2 inhibitors and the incidence of ovarian cancer in a population with type 2 diabetes mellitus (T2DM).
Material and methods:
A retrospective cohort study was conducted, and patients with T2DM were divided into those who used SGLT2 inhibitors and those who did not. A total of 163 668 and 327 336 patients with T2DM were categorized into the SGLT2 inhibitor and control groups, respectively. The primary outcome was the development of ovarian cancer, as identified using diagnostic codes and laboratory examination findings. Cox proportional hazard regression was adopted to yield the adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for ovarian cancer events between the two groups.
Results:
A total of 167 and 222 patients developed ovarian cancer in the SGLT2 inhibitor and control groups, respectively. The incidence of ovarian cancer was significantly lower in the SGLT2 inhibitor group than in the control group (adjusted hazard ratio: 0.73, 95% CI: 0.60–0.89, p = 0.0023). Subgroup analysis stratified by oral medications revealed that the effect of SGLT2 inhibitors on ovarian cancer development was significantly different from the effects of biguanides, sulfonylureas, -glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors (p < 0.05).
Conclusions:
This preliminary study showed that the administration of SGLT2 inhibitors in patients with T2DM is associated with a lower incidence of ovarian cancer.
REFERENCES (39)
1.
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50.
2.
Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol 2020; 18: 104-9.
3.
Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovasc Diabetol 2022; 21: 83.
4.
Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health 2019; 16: 2965.
5.
Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 2021; 398: 262-76.
6.
Li D, Shi W, Wang T, Tang H. SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2018; 20: 1972-6.
7.
Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 2020; 17: 761-72.
8.
Jiang K, Xu Y, Wang D, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell 2022; 13: 336-59.
9.
Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol 2021; 83: 503-28.
10.
Sha W, Wen S, Chen L, Xu B, Lei T, Zhou L. The role of SGLT2 inhibitor on the treatment of diabetic retinopathy. J Diabetes Res 2020; 2020: 8867875.
11.
Chung JF, Yang PJ, Chang CK, et al. The use of sodium-glucose cotransporter 2 inhibitors and the incidence of uveitis in type 2 diabetes: a population-based cohort study. Arch Med Sci 2024; 20: 402-9.
12.
Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotectiveeffect of SGLT2 inhibitors. Molecules 2021; 26: 7213.
13.
Yao YP, Yang PJ, Lee CY, Huang JY, Yang SF, Lin HY. Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus. Int J Med Sci 2023; 20: 1705-10.
14.
Su YC, Hung JH, Chang KC, et al. Comparison of sodium-glucose cotransporter 2 inhibitors vs glucagonlike peptide-1 receptor agonists and incidence of dry eye disease in patients with type 2 diabetes in Taiwan. JAMA Netw Open 2022; 5: e2232584.
15.
Long Q, Li L, Yang H, et al. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol 2022; 110: 109024.
16.
Winiarska A, Knysak M, Nabrdalik K, Gumprecht J, Stompór T. Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists. Int J Mol Sci 2021; 22: 10822.
17.
Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 2019; 18: 15.
18.
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs 2019; 35: 151-6.
19.
Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician 2009; 80: 609-16.
20.
Wang L, Wang L, Zhang J, Wang B, Liu H. Association between diabetes mellitus and subsequent ovarian cancer in women: a systematic review and meta-analysis of cohort studies. Medicine (Baltimore). 2017; 96: e6396.
21.
Zhang D, Zhao Y, Wang T, Xi Y, Li N, Huang H. Diabetes mellitus and long-term mortality of ovarian cancer patients. A systematic review and meta-analysis of 12 cohort studies. Diabetes Metab Res Rev 2017; 33. doi: 10.1002/dmrr.2868.
23.
Saed GM, Diamond MP, Fletcher NM. Updates of the role of oxidative stress in the pathogenesis of ovarian cancer. Gynecol Oncol 2017; 145: 595-602.
24.
Ding DN, Xie LZ, Shen Y, et al. Insights into the role of oxidative stress in ovarian cancer. Oxid Med Cell Longev 2021; 2021: 8388258.
25.
Komatsu S, Nomiyama T, Numata T, et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J 2020; 67: 99-106.
26.
Kaji K, Nishimura N, Seki K, et al. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 2018; 142: 1712-22.
27.
Rooth C. Ovarian cancer: risk factors, treatment and management. Br J Nurs 2013; 22: S23-30.
28.
Xing YJ, Liu BH, Wan SJ, et al. A SGLT2 inhibitor dapagliflozin alleviates diabetic cardiomyopathy by suppressing high glucose-induced oxidative stress in vivo and in vitro. Front Pharmacol 2021; 12: 708177.
29.
Yang Z, Li T, Xian J, et al. SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy. FASEB J 2022; 36: e22410.
30.
Brieger KK, Phung MT, Mukherjee B, et al. High prediagnosis inflammation-related risk score associated with decreased ovarian cancer survival. Cancer Epidemiol Biomarkers Prev 2022; 31: 443-52.
31.
Anastasio C, Donisi I, Del Vecchio V, et al. SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells. Cell Mol Biol Lett 2024; 29: 80.
32.
Ali A, Mekhaeil B, Biziotis OD, et al. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun Biol 2023; 6: 919.
33.
Naeimzadeh Y, Tajbakhsh A, Nemati M, Fallahi J. Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies. Eur J Pharmacol 2024; 978: 176803.
34.
Zheng J, Lu J, Qi J, et al. The effect of SGLT2 inhibition on prostate cancer: Mendelian randomization and observational analysis using electronic healthcare and cohort data. Cell Rep Med 2024; 5: 101688.
35.
Luo J, Hendryx M, Dong Y. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival. Br J Cancer 2023; 128: 1541-7.
36.
La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev 2017; 26: 55-62.
37.
Nelinson DS, Sosa JM, Chilton RJ. SGLT2 inhibitors: a narrative review of efficacy and safety. J Osteopath Med 2021; 121: 229-39.
38.
Mahtta D, Ramsey DJ, Lee MT, et al. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the Department of Veterans Affairs. Diabetes Care 2022; 45: 372-80.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
